Abstract Library

#3072 Rb and p53 Status Determination by Immunochemistry Is Complementary in Routine Practice to Genetic Testing of Neuroendocrine Neoplasms

Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: Chen R, Lacroix L, De Rycke O, Lacombe C, Cazes A,

Keywords: rb, p53, aggressive neuroendocrine tumors, biomarker,

#2904 Prognosis and Management of Advanced Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors (G3 NETs): A NET-CONNECT Study Performed in Four Expert Centers

Introduction: G3 NETs are rare tumors with poorly defined prognosis and management.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: de Mestier L, Lamarca A, Hernando-Cubero J, Alonso Gordoa T, Cros J,

Keywords: grade 3, prognosis, treatment, alkylating agents,

#2874 Role of FOXM1 in Aggressive Pancreatic / Pulmonary Neuroendocrine Carcinomas and Anti-Tumor Effect of the FOXM1 Inhibitor Thiostrepton

Introduction: DNA-targeting agents are the main treatment of aggressive pulmonary and pancreatic neuroendocrine carcinomas (NEC). FOXM1 is a transcription factor controlling cell proliferation and DNA repair pathways, playing therefore an important role in tumor progression and chemoresistance.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: De Rycke O, Raffenne J, Lacombe C, Hentic O, Gounant V,

Keywords: neuroendocrine carcinoma, FOXM1, DNA repair, anti-tumor drug,

#2870 When It Comes to the Diagnostic of Neuroendocrine Neoplasms (NEN), Not All Markers and Clones Were Made Equal. Assessment of 5 Makers in 466 NEN from 10 Anatomical Sites

Introduction: Histological diagnostic of neuroendocrine neoplasms (NEN) relies on morphological criteria and expression of several neuroendocrine marker assessed by immunohistochemistry. Systematic large evaluation of classical (chromogranin A (chrA), synaptophysin (Syn), CD56) and emerging (chromogranin B (chrB), INSM1) markers are lacking.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: Mamodaly M, Chen R, Cazes A, Guedj N, Deschamps L,

Keywords: Neuroendocrine markers, Chromogranin A, Chromogranin B, INSM1,

#2293 Genomic and Transcriptomic Characterization of Aggressive Well Differentiated Pancreatic Neuroendocrine Tumors (WD PanNET)

Introduction: While the genomic and transcriptomic landscape of low proliferating PanNET have been well studied, pathways driving aggressive WD PanNET are still unclear.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Cros J, Soukeur M, Raffenne J, Bernard V, Scoazec J,

Keywords: Exome sequencing, Pancreatic NET, G3 NET,